Your browser doesn't support javascript.
loading
The not so innocent bystander: an unusual cause of progressive breathlessness.
Lyon, Max; Whiteway, Alastair; Darby, Michael; Bhatt, Nidhi; Barratt, Shaney L.
Afiliação
  • Lyon M; Department of Respiratory Medicine, North Bristol NHS Trust, Westbury on Trym, Bristol, UK.
  • Whiteway A; Department of Haematology, North Bristol NHS Trust, Westbury on Trym, Bristol, UK.
  • Darby M; Department of Radiology, North Bristol NHS Trust, Bristol, UK.
  • Bhatt N; Cellular Pathology, North Bristol NHS Trust, Bristol, UK.
  • Barratt SL; Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol, UK mdzslb@bristol.ac.uk.
Thorax ; 2021 Jan 21.
Article em En | MEDLINE | ID: mdl-33479041
ABSTRACT
This case report discusses a 76-year-old man who presented with symptomatic diffuse alveolar-septal and tracheobronchial amyloidosis with a low-grade monoclonal gammopathy. This patient had a combination of both symptomatic diffuse alveolar-septal interstitial disease and tracheobronchial amyloidosis, features that contradict the widely accepted presentations seen in this disease. First, tracheobronchial amyloidosis has been documented as localised disease without systemic involvement. Second, diffuse alveolar-septal interstitial disease is rarely identified with clinical symptoms unless there is significant cardiac involvement. This case highlights a number learning points in the diagnosis and management of systemic amyloid light chain amyloidosis;(1) There is a need for a high index of suspicion for diagnosis due to the potential subtlety of a plasma cell clone underlying AL amyloidosis, requiring serum-free light chain assays to increase sensitivity; (2) Haematological response and recovery of organ dysfunction are not a linear relationship due to the slower reversal of amyloid deposition; therefore, ongoing monitoring is required to identify those in need of repeated therapy. However, haematological response is a marker of overall survival and (3) Multisystem assessment and multidisciplinary collaboration are critical in optimising the care of patients with systemic AL amyloidosis.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article